{"mainPropery":{"diseaseId":7103,"diseaseName":"Multicentric reticulohistiocytosis","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/7103/multicentric-reticulohistiocytosis","synonyms":[],"synonyms-with-source":[],"identifiers":[{"identifierType":"ORPHANET","identifierId":"139436"},{"identifierType":"UMLS","identifierId":"C0311284"}]},"diseaseCategories":[{"diseaseTypeId":22,"diseaseTypeName":"Skin Diseases","source":"Orphanet"}],"organizations":[{"resourceID":73,"resourceName":"Histiocytosis Association","abbreviation":"","address1":"332 North Broadway","address2":"","address3":"","address4":"","address5":"","city":"Pitman","state":"NJ","zip":"08071 ","country":"United States","phone":"+1-856-589-6606","tty":"","tollFree":"1-800-548-2758 (from US and Canada)","fax":"+1-856-589-6614","email":"info@histio.org","url":"https://www.histio.org/","freeText":""},{"resourceID":74,"resourceName":"Histiocytosis Association of Canada","abbreviation":"","address1":"41 Milverton Close","address2":"Waterdown, ON  ","address3":"L8B 0A9 ","address4":"","address5":"","city":"","state":"","zip":"","country":"Canada","phone":"","tty":"","tollFree":"","fax":"","email":"info@histio.ca","url":"https://histiocytosis.ca/","freeText":""},{"resourceID":103,"resourceName":"Arthritis Foundation","abbreviation":"","address1":"1355 Peachtree St. NE","address2":"6th Floor","address3":"","address4":"","address5":"","city":"Atlanta","state":"GA","zip":"30309","country":"United States","phone":"+1-404-872-7100","tty":"","tollFree":"1-844-571-HELP (4357)","fax":"","email":"","url":"https://www.arthritis.org","freeText":""}],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=multicentric%20reticulohistiocytosis%20%5Bti%5D' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Multicentric reticulohistiocytosis. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/283885-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139436' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1550,"resourceId":2178,"resourceName":"DermNet New Zealand","descriptionText":"<a href='http://dermnetnz.org/dermal-infiltrative/reticulohistiocytosis.html' target='_blank'>DermNet NZ</a> is an online resource about skin diseases developed by the New Zealand Dermatological Society Incorporated. DermNet NZ provides information about this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1591,"resourceId":2206,"resourceName":"Facebook Groups","descriptionText":"Visit the <a href='https://www.facebook.com/groups/268882663128991' target='_blank'>Multicentric Reticulohistiocytosis</a> group on Facebook.","resourceClassificationName":"Organizations","resourceClassificationSectionName":"Social Networking Websites"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:11824' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2722,"resourceId":4053,"resourceName":"Patient Registry","descriptionText":"A registry supports research by collecting of information about patients that share something in common, such as being diagnosed with Multicentric reticulohistiocytosis. The type of data collected can vary from registry to registry and is based on the goals and purpose of that registry. Some registries collect contact information while others collect more detailed medical information. <a href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries\" target=\"_blank\">Learn more about registries</a>.<br />\r\n<br />\r\nRegistries for&nbsp;Multicentric reticulohistiocytosis:<br />\r\n<a href='https://histiocytesociety.org/IRHDR' target='_blank'>International Rare Histiocytic Disorders Registry (IRHDR)</a><br />&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"}],"overviewQuestion":{"questionId":360,"questionText":"What is&nbsp;multicentric reticulohistiocytosis? ","answerText":"<strong>Multicentric reticulohistiocytosis</strong> is a disease&nbsp;that is characterized by the presence of <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003233.htm\" target=_blank>papules</a> and <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003230.htm\" target=_blank>nodules</a> and associated with <a href=\"http://www.medterms.com/script/main/art.asp?articlekey=25247\" target=_blank>arthritis mutilans</a>.[263]&nbsp;The disease can involve the skin, the bones, the tendons, the muscles, the joints, and nearly any other organ (e.g., eyes, larynx, thyroid, salivary glands, bone marrow, heart, lung, kidney, liver, gastrointestinal tract). In the majority of cases, the cause of&nbsp;multicentric reticulohistiocytosis&nbsp;is unknown; however, it has been associated with an underlying&nbsp;cancer in about one fourth of cases, suggesting that&nbsp;it&nbsp;may be a&nbsp;<a href=\"http://www.ninds.nih.gov/disorders/paraneoplastic/paraneoplastic.htm\" target=_blank>paraneoplastic syndrome</a>.[264][265]","dateModified":"2012-09-28T15:41:00"},"basicQuestions":[{"questionId":361,"questionText":"What are the symptoms of multicentric reticulohistiocytosis?","answerText":"The&nbsp;main symptoms&nbsp;of&nbsp;multicentric reticulohistiocytosis&nbsp;are arthritis and red to purple skin nodules varying in size from 1 to 10 mm. The nodules&nbsp;can be&nbsp;found&nbsp;on any part of the&nbsp;body but tend to concentrate on the face and hands and decrease in number from head to toe.[264][267] The arthritis is most often symmetrical and polyarticular (affecting many joints). Unlike adult <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm\" target=_blank>rheumatoid arthritis</a>, it does not spare the&nbsp;joints closest to the fingertips. It can be severely destructive, and in one third of cases it progresses to <a href=\"http://www.medterms.com/script/main/art.asp?articlekey=25247\" target=_blank>arthritis multilans</a>. Further history reveals that approximately one third of patients complain of symptoms such as fever, weight loss, and <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003089.htm\" target=_blank>malaise</a>; less often, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000182.htm\" target=_blank>pericarditis</a> and <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001245.htm\" target=_blank>myositis</a> are present.[264][267] \r\n<p>The clinical presentation of multicentric reticulohistiocytosis is <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002382.htm\" target=_blank>insidious</a> in onset and begins with arthritic complaints in approximately two thirds of patients.&nbsp; It is potentially one of the most rapidly destructive forms of arthritis. Joint involvement remits and relapses, gradually worsening into a debilitating and permanent&nbsp;<a href=\"http://www.medterms.com/script/main/art.asp?articlekey=25247\" target=_blank>arthritis multilans</a>.&nbsp; The severity of the damage has been reported to be&nbsp;related to the age of onset; therefore, the earlier one has symptoms, the more severe the symptoms tend to be.&nbsp; Like the associated arthritis,&nbsp;skin lesions tend to wax and wane until the disease spontaneously resolves, but may leave permanent disfigurement.[267]</p>","dateModified":"2013-06-21T16:04:00","resourceClassificationName":"Symptoms","references":[{"referenceId":264,"authors":"West SG","articleTitle":"Chapter 297 -- Systemic Diseases in Which Arthritis is a Feature","bookWebsiteJournalTitle":"Goldman: Cecil Textbook of Medicine, 23rd ed.","date":"2008","authors2":"","placeOfPublication":"Philadelphia, PA","publisher":"Saunders Elsevier"},{"referenceId":267,"authors":"Hsiung et al.","articleTitle":"Multicentric reticulohistiocytosis presenting with clinical features of dermatomyositis","bookWebsiteJournalTitle":"Journal of the American Academy of Dermatology","date":"2003"}]},{"questionId":364,"questionText":"How might multicentric reticulohistiocytosis be treated?","answerText":"Dermatologists and rheumatologists are often the types of specialists that oversee the treatment of patients with multicentric reticulohistiocytosis. Although no specific therapy has consistently been shown to improve multicentric reticulohistiocytosis,&nbsp;many different drugs have been used.[265] For instance,&nbsp;therapy with <a href=\"http://www.fda.gov/CDER/Drug/infopage/COX2/NSAIDmedguide.htm\" target=_blank>non-steroidal anti-inflammatory agents</a>&nbsp;(e.g., aspirin or ibuprofen) may help the arthritis.&nbsp;<a href=\"http://www.dermnetnz.org/treatments/systemic-steroids.html\" target=_blank>Systemic corticosteroids</a> and/or cytotoxic agents, particularly <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682080.html\" target=_blank>cyclophosphamide</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682899.html\" target=_blank>chlorambucil</a>, or <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682019.html\" target=_blank>methotrexate</a>, may affect the inflammatory response, prevent further joint destruction, and cause skin lesions to regress.&nbsp;Antimalarials (e.g., <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601240.html\" target=_blank>h</a><span class=content><span class=b1><a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601240.html\" target=_blank>ydroxychloroquine</a> and <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a603030.html\" target=_blank>mefloquine</a>) </span></span>have also been used.&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601011.html\" target=_blank>Alendronate</a> and other bisphosphonates have been reported to be effective in at least one patient and&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a602013.html\" target=_blank>etanercept</a> and <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a604023.html\" target=_blank>infliximab</a> have been effective in some.[266] ","dateModified":"2013-06-21T16:05:00","resourceClassificationName":"Treatment","references":[{"referenceId":265,"authors":"Rapini RP, Morgan LT","articleTitle":"Dermatologic Manifestations of Multicentric Reticulohistiocytosis ","bookWebsiteJournalTitle":"Medscape Reference ","date":"June 6, 2012","url":"http://emedicine.medscape.com/article/1058248-overview","dateAccessed":"2012-09-28T00:00:00"},{"referenceId":266,"authors":"Callen JP","articleTitle":"Multicentric Reticulohistiocytosis","bookWebsiteJournalTitle":"Medscape Reference","date":"August 16, 2011","url":"http://emedicine.medscape.com/article/283885-overview","dateAccessed":"2012-09-28T00:00:00"}]},{"questionId":365,"questionText":"What is the prognosis for individuals with multicentric reticulohistiocytosis?","answerText":"After an average course of 8 years, patients often go into remission (a state where symptoms have subsided). The disease can cause considerable morbidity (disability as a result of the disease), mainly related to the occurrence of severe arthritis. The arthritis can come and go, but it can be very severe in about 45% of cases.[265]&nbsp;If the patient has an associated cancer, the prognosis relates to that of the specific cancer.[266]","dateModified":"2013-06-21T16:06:00","resourceClassificationName":"Prognosis","references":[{"referenceId":265,"authors":"Rapini RP, Morgan LT","articleTitle":"Dermatologic Manifestations of Multicentric Reticulohistiocytosis ","bookWebsiteJournalTitle":"Medscape Reference ","date":"June 6, 2012","url":"http://emedicine.medscape.com/article/1058248-overview","dateAccessed":"2012-09-28T00:00:00"},{"referenceId":266,"authors":"Callen JP","articleTitle":"Multicentric Reticulohistiocytosis","bookWebsiteJournalTitle":"Medscape Reference","date":"August 16, 2011","url":"http://emedicine.medscape.com/article/283885-overview","dateAccessed":"2012-09-28T00:00:00"}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":8231,"relatedDiseaseName":"Non-Langerhans-Cell Histiocytosis","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[{"caseId":39967,"abbreviatedInquiry":"I am in contact with people from&nbsp;around the world with MRH through Facebook.&nbsp; Many of us have intermittent itching. Can you address this issue? Thank you.","caseQuestions":[{"questionId":6925,"questionText":"Is&nbsp;itchy skin&nbsp;(pruritus) known to be associated with&nbsp;multicentric reticulohistiocytosis?","answerText":"Yes. It has been estimated that about 1 in 3 people with&nbsp;multicentric reticulohistiocytosis&nbsp;report&nbsp;that they experience pruritus.[265]","dateModified":"2013-06-24T14:08:00","references":[{"referenceId":265,"authors":"Rapini RP, Morgan LT","articleTitle":"Dermatologic Manifestations of Multicentric Reticulohistiocytosis ","bookWebsiteJournalTitle":"Medscape Reference ","date":"June 6, 2012","url":"http://emedicine.medscape.com/article/1058248-overview","dateAccessed":"2012-09-28T00:00:00"}]},{"questionId":6928,"questionText":"How might itchiness (pruritus)&nbsp;associated with&nbsp;multicentric reticulohistiocytosis be treated?","answerText":"When severe, pruritus can adversly&nbsp;affect daily living.&nbsp;Managing&nbsp;this symptom is important and may require long-term therapy.&nbsp;While the optimal treatment for&nbsp;multicentric reticulohistiocytosis associated pruritus is&nbsp;not currently known, you may find the following article to be a helpful resource. This article reviews current approaches to treating pruritus associated with&nbsp;paraneoplastic skin diseases. It explores the use of selective serotonin reuptake inhibitors, selective neuroepinephrine re-uptake inhibitors, ultraviolet therapy, and combination therapies&nbsp;for treatment of chronic itch. We recommend that you review this article with your healthcare provider.<br><br>Yosipovitch G.&nbsp;<a href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150589/\" target=_blank>Chronic pruritus: a paraneoplastic sign</a>. <em>Dermatol Ther</em>. 2010 Nov-Dec;23(6):590-6. Click on the title&nbsp;to view the full-text article.","dateModified":"2013-06-24T14:42:00","resourceClassificationName":"Treatment","references":[]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":5670,"phenoTypeName":"Arthritis","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":11811,"phenoTypeName":"Histiocytosis","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":959,"phenoTypeName":"Skin nodule","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":3609,"phenoTypeName":"Cachexia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13043,"phenoTypeName":"Fever","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9419,"phenoTypeName":"Muscle weakness","frequencyText":"Occasional","percentRanges":"5%-29%"}],"medicalProducts":[],"EncodedName":"Multicentric_reticulohistiocytosis"}